Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Tenaya Therapeutics, retaining the price target of $5.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Pantginis has given his Buy rating due to a combination of factors related to Tenaya Therapeutics’ recent clinical and regulatory developments. The interim data from the MyPeak-1 study, presented at the American Heart Association Scientific Sessions 2025, demonstrated promising results for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy. The study showed mechanistic proof-of-concept with sustained myocardial vector transduction and improvements in safety, which led to a green light for dose expansion.
Furthermore, the safety data indicated that TN-201 was well tolerated at both tested doses, with no dose-limiting toxicities observed. The increase in MyBP-C protein levels and the improvement in multiple clinical parameters among patients further strengthen the therapy’s clinical profile. Despite a procedural FDA clinical hold, Pantginis views it as a short-term issue, expecting it to be resolved without impacting the therapy’s potential. These factors collectively underpin the Buy rating for Tenaya Therapeutics.
In another report released on November 4, LifeSci Capital also maintained a Buy rating on the stock with a $3.00 price target.